The results of our meta‐analysis show that PD‐1 and PD‐L1 inhibitors have similar treatment efficacy for NSCLC (HR 0.71, 95% CI 0.59–0.86; HR 0.73, 95% CI 0.63–0.82, respectively; P = 0.84, I2 = 0%). Here, CD274 is linked to non-small cell lung carcinoma.